Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Farrukh T Awan, MD, MS, John M. Pagel, MD, PhD, Leslie A Andritsos, MD, Ajay K. Gopal, MD, Richard R. Furman, MD, Stephen Spurgeon, MD, Delva Deauna-Limayo, MD, Scott Stromatt, MD, John C. Byrd, MD

Blood (2011) 118 (21): 1792.

https://doi.org/10.1182/blood.V118.21.1792.1792

Published: 2011

Journal Articles

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Delva Deauna-Limayo, MD, Omar Aljitawi, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Jo Wick, Joseph McGuirk, DO

Blood (2010) 116 (21): 1335.

https://doi.org/10.1182/blood.V116.21.1335.1335

Published: 2010

Journal Articles

GCSF Alone or in Combination with Cyclophosphamide (C) or GM-CSF for Hematopoietic Stem Cell Mobilization (HSCM) for Autologous Peripheral Blood Stem Cell Transplant (AHPCT): A Retrospective Review of a Single Center Experience

Sunil Abhyankar, Barry Skikne, Delva Deauna, Dean Merkel, David Bodensteiner, Omar Aljitawi, Sid Ganguly, Joseph Mcguirk

Blood (2008) 112 (11): 4127.

https://doi.org/10.1182/blood.V112.11.4127.4127

Published: 2008

Journal Articles

Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).

Delva Deauna-Limayo, MD, Suman Kambhampathi, MD, David Bodensteiner, MD, Siddharta Ganguly, MD, Barry Skikne, MD, Karen Wolfe, Holly Smith, Ron Krebill, Dean Merkel, Da Zhang, MD, Carol Blecke, Sarah Spencer, Matthew Mayo

Blood (2007) 110 (11): 3619.

https://doi.org/10.1182/blood.V110.11.3619.3619

Published: 2007

Journal Articles

Rituximab Treatment Affords Long Term Control in Thrombotic Thrombocytopenic Purpura (TTP): The University of Kansas Experience.

Meenakshi Thirunavu, MD, Delva Deauna-Limayo, MD, Jigar Patel, MD, David C. Bodensteiner, MD, Barry S. Skikne, MD, Siddhartha S. Ganguly, MD, Norma Lacy, Mervyn A. Sahud, MD

Blood (2006) 108 (11): 1055.

https://doi.org/10.1182/blood.V108.11.1055.1055

Published: 2006

Journal Articles

Pegylated Liposomal Doxorubicin (Doxil ® ), Dexamethasone and Low Dose Thalidomide (DDt) as Therapy for Newly Diagnosed Multiple Myeloma.

Delva Deauna-Limayo, MD, Omar S. Aljitawi, MD, Mathew Mayo, PhD, David C. Bodensteiner, MD, Siddhartha Ganguly, MD, Barry S. Skikne, MD, Kambhampati Suman, MD

Blood (2005) 106 (11): 5164.

https://doi.org/10.1182/blood.V106.11.5164.5164

Published: 2005

Journal Articles

A Single Institution Long-Term Experience Using Autologous Stem Cell Transplantation for the Management of Hodgkin’s Lymphoma.

Barry S. Skikne, MD, Narotham Thudi, MD, Delva Deauna-Limayo, MD, Siddhartha Ganguly, MD, David Bodensteiner, MD, Clint L. Divine, James D. Cook, MD

Blood (2004) 104 (11): 5233.

https://doi.org/10.1182/blood.V104.11.5233.5233

Published: 2004

NARROW

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

GCSF Alone or in Combination with Cyclophosphamide (C) or GM-CSF for Hematopoietic Stem Cell Mobilization (HSCM) for Autologous Peripheral Blood Stem Cell Transplant (AHPCT): A Retrospective Review of a Single Center Experience

Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).

Rituximab Treatment Affords Long Term Control in Thrombotic Thrombocytopenic Purpura (TTP): The University of Kansas Experience.

Pegylated Liposomal Doxorubicin (Doxil ® ), Dexamethasone and Low Dose Thalidomide (DDt) as Therapy for Newly Diagnosed Multiple Myeloma.

A Single Institution Long-Term Experience Using Autologous Stem Cell Transplantation for the Management of Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

GCSF Alone or in Combination with Cyclophosphamide (C) or GM-CSF for Hematopoietic Stem Cell Mobilization (HSCM) for Autologous Peripheral Blood Stem Cell Transplant (AHPCT): A Retrospective Review of a Single Center Experience

Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).

Rituximab Treatment Affords Long Term Control in Thrombotic Thrombocytopenic Purpura (TTP): The University of Kansas Experience.

Pegylated Liposomal Doxorubicin (Doxil ® ), Dexamethasone and Low Dose Thalidomide (DDt) as Therapy for Newly Diagnosed Multiple Myeloma.

A Single Institution Long-Term Experience Using Autologous Stem Cell Transplantation for the Management of Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only